ReviewBiology of reproduction2022
The placenta as a target of opioid drugs†.
Review in Biology of reproduction, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 24 citations in OpenAlex.
- Transcriptomic Reprogramming of the Human Placenta Following Maternal Opioid Exposure: Identification of Altered Metabolic and Translational Pathways.Current issues in molecular biology · 2026Article
- Limbic System Microstructure in Neonates With Antenatal Opioid Exposure.JAMA network open · 2026Article
- Review
- Maternal opioid use and hepatitis C infection disrupt the placental immune landscape and structure.JCI insight · 2026Article
- Delineating the effects of prenatal oxycodone exposure and melatonin treatment on placental and fetal outcomes in pregnant rats.bioRxiv : the preprint server for biology · 2026Article
- The placenta as a window into neonatal brain injury.Seminars in perinatology · 2025Review
- Maternal opioid use is associated with altered placental bacterial DNA and activation of immune-apoptotic pathways.NeuroImmune pharmacology and therapeutics · 2025Article
- Fentanyl exposure during preconception and gestation permanently dysregulates endogenous opioid peptides and sympathoadrenal-medullary axis in the offspring.Clinical science (London, England : 1979) · 2025Article
- Maternal opioid use with and without hepatitis C infection disrupts the structure and immune landscape of the maternal-fetal interface.bioRxiv : the preprint server for biology · 2025Article
- Risk of adverse obstetrical and neonatal outcomes in women consuming recreational drugs during pregnancy.BMC pregnancy and childbirth · 2025Observational
- Buprenorphine induces human fetal membrane sterile inflammation.Journal of reproductive immunology · 2025Article
- Peripartum buprenorphine and oxycodone exposure impair maternal behavior and increase neuroinflammation in new mother rats.Brain, behavior, and immunity · 2025Article
- Gestational Opioid Exposure: From Morphine to MOUD - How Opioids Impact Offspring Development and Maternal Care.Current topics in behavioral neurosciences · 2025Review
- Epigenome-wide association study of placental co-methylated regions in newborns for prenatal opioid exposure.Environmental epigenetics · 2025Article
- Effects of oxycodone on placental lineages: Evidence from the transcriptome profile of mouse trophoblast giant cells.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Investigating the neurobiology of maternal opioid use disorder and prenatal opioid exposure using brain organoid technology.Frontiers in cellular neuroscience · 2024Review
- Placental volume in pregnant women with opioid use: prenatal MRI assessment.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2023Article
- Developmental outcomes with perinatal exposure (DOPE) to prescription opioids.NeuroImmune pharmacology and therapeutics · 2023Review
- The impact of opioids on the transcriptional landscape of human villous trophoblasts.Placenta · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Opioid drugs are analgesics increasingly being prescribed to control pain associated with a wide range of causes. Usage of pregnant women has dramatically increased in the past decades. Neonates born to these women are at risk for neonatal abstinence syndrome (also referred to as neonatal opioid withdrawal syndrome). Negative birth outcomes linked with maternal opioid use disorder include compromised fetal growth, premature birth, reduced birthweight, and congenital defects. Such infants require lengthier hospital stays necessitating rising health care costs, and they are at greater risk for neurobehavioral and other diseases. Thus, it is essential to understand the genesis of such disorders. As the primary communication organ between mother and conceptus, the placenta itself is susceptible to opioid effects but may be key to understanding how these drugs affect long-term offspring health and potential avenue to prevent later diseases. In this review, we will consider the evidence that placental responses are regulated through an endogenous opioid system. However, maternal consumption of opioid drugs can also bind and act through opioid receptors express by trophoblast cells of the placenta. Thus, we will also discuss the current human and rodent studies that have examined the effects of opioids on the placenta. These drugs might affect placental hormones associated with maternal recognition of pregnancy, including placental lactogens and human chorionic gonadotropin in rodents and humans, respectively. A further understanding of how such drugs affect the placenta may open up new avenues for early diagnostic and remediation approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.